Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10479144 | 0.87 | TLR8 (0.53) | TLR8DHFR | |
| SCHEMBL5398097 | 0.87 | TLR8 (0.53) | TLR8DHFR | |
| SCHEMBL14072496 | 0.82 | KCNH2 (0.56) | DHFR | |
| SCHEMBL11607678 | 0.81 | TLR8 (0.45) | TLR8 | |
| SCHEMBL19625906 | 0.79 | TLR8 (0.50) | TLR8 | |
| SCHEMBL4431622 | 0.77 | DHFR (0.54) | DHFR | |
| SCHEMBL3397263 | 0.77 | TLR8 (0.47) | TLR8 | |
| SCHEMBL15075239 | 0.76 | DHFR (0.50) | DHFR | |
| SCHEMBL6910786 | 0.76 | TLR8 (0.51) | TLR8DHFR | |
| SCHEMBL1063172 | 0.75 | TLR8 (0.49) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835445-B2 | Dihydrofolate reductase inhibitors | TRIUS THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2011153310-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | TRIUS THERAPEUTICS (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136014-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | DHFR, DPYD, DHODH | TLR8 3252/4885DHFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.